China is in talks with Pfizer to secure a licence that will permit domestic drugmakers to manufacture and distribute generic version of the U.S. firm's Covid drug as cases surge. Watch this video to know more.

China in talks with Pfizer for generic Covid drug, says reports

<p>The "Paxlovid rebound" phenomenon has taken centre-stage&nbsp;after US President Joe Biden experienced a "rebound" case of COVID-19 last weekend after taking the drug.</p>

<p>The US president was detected with coronavirus again on Saturday even as White House physician Kevin O’Connor said the president hadn't experienced any reemergence of symptoms. O’Connor declared that there was no need to re-initiate treatment for the president.</p>

<p><a href="https://www.wionews.com/world/pfizer-reports-record-profits-amid-growth-in-vaccine-paxlovid-pill-476179">Also Read:&nbsp;Pfizer reports record profits amid growth in vaccine, Paxlovid pill</a></p>

<p>Reports claim Biden has taken booster doses. Biden in a tweet said it "happens with a small minority of folks" while declaring that he had no symptoms. Dr Anthony Fauci who had taken Paxlovid reportedly also experienced a "Paxlovid rebound".&nbsp;</p>

<p><strong>What is "Paxlovid rebound"?</strong></p>

<p>According to a study, Pfizer's antiviral drug Paxlovid has caused a "rebound" of the virus in some cases. The US Centers for Disease Control and Prevention (CDC) had earlier issued an update on virus rebound stating that Paxlovid is recommended for early stage treatment of mild to moderate COVID-19 cases which are at high risk of progression to&nbsp;severe disease.</p>

<p><strong>Watch:&nbsp;Biden tests positive for COVID-19 again, returns to isolation</strong></p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/us-president-joe-biden-tests-positive-for-covid-19-again-returns-to-isolation-502192/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

<p>Coronavirus "rebound" is characterized with the recurrence of symptoms after a person tests negative.</p>

<p>The CDC said Paxlovid prevented hospitalisation, however it added that the virus rebound has been reported to occur between two and eight days after initial recovery and "is characterised by the recurrence of COVID-19 symptoms or a new positive viral test after having tested negative."</p>

<p>"A brief return of symptoms may be part of the natural history of virus in infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status," it said in its advisory. The US health agency added that it led to "mild illness" and there were no reports of "severe disease" with "no evidence" that additional treatment was needed with Paxlovid.</p>

<p><strong>What is Paxlovid?</strong></p>

<p>It is an oral antiviral drug and is available under Emergency Use Authorisation (EUA) by the US Food and Drug Administration (FDA). It is meant for adults and pediatric patients 12 years and older.</p>

<p>The CDC recommends the treatment should begin within five days as symptoms occur for people who have one or more risk of progression to severe disease. The CDC cautioned the patient should not display evidence of severe renal or hepatic impairment and should not be hospitalised at the time of treatment.</p>

<p>(With inputs from Agencies)</p>

<p><strong>WATCH WION LIVE HERE</strong></p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/us-president-joe-biden-tests-positive-for-covid-19-again-returns-to-isolation-502192/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>


The "Paxlovid rebound" phenomenon has taken centre-stage after US President Joe Biden experienced a "rebound" case of COVID-19 last weekend after taking the drug.

The "Paxlovid rebound" phenomenon has taken centre-stage after US President Joe Biden experienced a "rebound" case of COVID-19 last weekend after taking the drug. The US president was detected with coronavirus again on Saturday even as White House physician Kevin O’Connor said the president hadn't experienced any reemergence of symptoms. O’Connor declared that there was no need to re-initiate treatment for the president. Also Read: Pfizer reports record profits amid growth in vaccine, Paxlovid pill Reports claim Biden has taken booster doses. Biden in a tweet said it "happens with a small minority of folks" while declaring that he had no symptoms. Dr Anthony Fauci who had taken Paxlovid reportedly also experienced a "Paxlovid rebound". What is "Paxlovid rebound"? According to a study, Pfizer's antiviral drug Paxlovid has caused a "rebound" of the virus in some cases. The US Centers for Disease Control and Prevention (CDC) had earlier issued an update on virus rebound stating that Paxlovid is recommended for early stage treatment of mild to moderate COVID-19 cases which are at high risk of progression to severe disease. Watch: Biden tests positive for COVID-19 again, returns to isolation Coronavirus "rebound" is characterized with the recurrence of symptoms after a person tests negative. The CDC said Paxlovid prevented hospitalisation, however it added that the virus rebound has been reported to occur between two and eight days after initial recovery and "is characterised by the recurrence of COVID-19 symptoms or a new positive viral test after having tested negative." "A brief return of symptoms may be part of the natural history of virus in infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status," it said in its advisory. The US health agency added that it led to "mild illness" and there were no reports of "severe disease" with "no evidence" that additional treatment was needed with Paxlovid. What is Paxlovid? It is an oral antiviral drug and is available under Emergency Use Authorisation (EUA) by the US Food and Drug Administration (FDA). It is meant for adults and pediatric patients 12 years and older. The CDC recommends the treatment should begin within five days as symptoms occur for people who have one or more risk of progression to severe disease. The CDC cautioned the patient should not display evidence of severe renal or hepatic impairment and should not be hospitalised at the time of treatment. (With inputs from Agencies) WATCH WION LIVE HERE

‘Paxlovid rebound’: Why is this Covid drug given to Biden controversial? Check details

<p>US drugmaker Pfizer reported a net income of $7.86 billion due to the COVID-19 vaccine and the Paxlovid pill.</p>

<p>The vaccine helped the drugmaker to report $13 billion in sales in the quarter as the Paxlovid pill brought in $1.5 billion helping to boost the company's revenue by 77 per cent. The profits of the company grew 61 per cent.</p>

<p>The adjusted earnings of the company stood at $1.62 per share in the first quarter which surpassed $1.49 projected by industry experts. The company's revenue was $25.66 billion which was above Wall Street's expectation of $24.1 billion.</p>

<p><a href="https://www.wionews.com/world/eu-authorises-moderna-vaccine-for-young-kids-recommends-pfizers-booster-458691">Also Read:&nbsp;EU authorises Moderna vaccine for young kids; recommends Pfizer's booster</a></p>

<p>Pfizer had launched its vaccine for adults in late 2020 in the US and later expanded it to include children.</p>

<p>The pharmaceutical giant had said last month that a third dose of the COVID-19 vaccine protection against the Omicron variant in children was meant for age group of 5 to 11.</p>

<p><strong>Watch:&nbsp;Biden calls Pfizer COVID-19 pill a 'gamechanger'</strong></p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/us-president-joe-biden-calls-pfizer-covid-19-pill-a-game-changer-442327/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

<p>The vaccine maker had added that it will apply for US emergency use authorization for the booster dose for the age group.</p>

<p>WATCH WION LIVE HERE</p>

<p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></p>


US drugmaker Pfizer reported a net income of $7.86 billion due to the COVID-19 vaccine and the Paxlovid pill. The vaccine helped the drugmaker to report $13 billion in sales in the quarter as the Paxlovid pill brought in $1.

US drugmaker Pfizer reported a net income of $7.86 billion due to the COVID-19 vaccine and the Paxlovid pill. The vaccine helped the drugmaker to report $13 billion in sales in the quarter as the Paxlovid pill brought in $1.5 billion helping to boost the company's revenue by 77 per cent. The profits of the company grew 61 per cent. The adjusted earnings of the company stood at $1.62 per share in the first quarter which surpassed $1.49 projected by industry experts. The company's revenue was $25.66 billion which was above Wall Street's expectation of $24.1 billion. Also Read: EU authorises Moderna vaccine for young kids; recommends Pfizer's booster Pfizer had launched its vaccine for adults in late 2020 in the US and later expanded it to include children. The pharmaceutical giant had said last month that a third dose of the COVID-19 vaccine protection against the Omicron variant in children was meant for age group of 5 to 11. Watch: Biden calls Pfizer COVID-19 pill a 'gamechanger' The vaccine maker had added that it will apply for US emergency use authorization for the booster dose for the age group. WATCH WION LIVE HERE

Pfizer reports record profits amid growth in vaccine, Paxlovid pill

<p>According to reports, an antiviral pill&nbsp;produced by a Japanese company showed "rapid clearance of the infectious COVID-19 virus".</p>

<p>The pharmaceutical company named Shionogi &amp; Co Ltd said phase two results showed improvement in respiratory and feverish symptoms with the phase-3 trial set for worldwide testing with US government support.</p>

<p><a href="https://www.wionews.com/trending/how-made-in-india-pill-dolo-650-became-indias-favourite-snack-in-covid-waves-445350">Also Read:&nbsp;How made-in-India pill Dolo 650 became India’s ‘favourite snack’ in Covid waves</a></p>

<p>The company reportedly aims to manufacture antiviral pills with Japanese regulators currently evaluating the drug.<br />
The drugmakers reported on the fourth day after taking the third dose, the patient reported a fall in viral infection.</p>

<p>The study did not report any adverse impact with phase two study conducted among 428 patients in Japan and South Korea.&nbsp;</p>

<p><strong>Watch:&nbsp;Biden calls Pfizer COVID-19 pill a 'Game Changer'</strong></p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/us-president-joe-biden-calls-pfizer-covid-19-pill-a-game-changer-442327/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

<p>Japanese Prime Minister Fumio Kishida had earlier indicated the government would fast track approval in order to ensure a potential new tool to fight the virus.</p>

<p>Reports say the pill reduced virus level by 80 per cent after four days of treatment compared to a placebo group. The&nbsp;virus level among patients who took smaller doses of the drug fell by 63 per cent, reports say.</p>

<p>The WHO had earlier recommended Pfizer’s COVID-19 antiviral pill Paxlovid for patients suffering from mild virus who were at risk of hospitalisation.</p>

<p>(With inputs from Agencies)</p>


According to reports, an antiviral pill produced by a Japanese company showed "rapid clearance of the infectious COVID-19 virus". The pharmaceutical company named Shionogi & Co Ltd said phase two results showed improvement in respiratory and feverish symptoms with the phase-3 trial set for worldwide testing with US government support.

According to reports, an antiviral pill produced by a Japanese company showed "rapid clearance of the infectious COVID-19 virus". The pharmaceutical company named Shionogi & Co Ltd said phase two results showed improvement in respiratory and feverish symptoms with the phase-3 trial set for worldwide testing with US government support. Also Read: How made-in-India pill Dolo 650 became India’s ‘favourite snack’ in Covid waves The company reportedly aims to manufacture antiviral pills with Japanese regulators currently evaluating the drug. The drugmakers reported on the fourth day after taking the third dose, the patient reported a fall in viral infection. The study did not report any adverse impact with phase two study conducted among 428 patients in Japan and South Korea. Watch: Biden calls Pfizer COVID-19 pill a 'Game Changer' Japanese Prime Minister Fumio Kishida had earlier indicated the government would fast track approval in order to ensure a potential new tool to fight the virus. Reports say the pill reduced virus level by 80 per cent after four days of treatment compared to a placebo group. The virus level among patients who took smaller doses of the drug fell by 63 per cent, reports say. The WHO had earlier recommended Pfizer’s COVID-19 antiviral pill Paxlovid for patients suffering from mild virus who were at risk of hospitalisation. (With inputs from Agencies)

Japan's antivirus pill shows 'rapid clearance' of COVID-19

pfizer-pill

Pfizer Pill, News on Pfizer Pill, stories on Pfizer Pill, articles on Pfizer Pill, Pfizer Pill stories at Wion, Pfizer Pill news, Pfizer Pill latest news

pfizer pill

China in talks with Pfizer for generic Covid drug, says reports

‘Paxlovid rebound’: Why is this Covid drug given to Biden controversial? Check details

Pfizer reports record profits amid growth in vaccine, Paxlovid pill

Japan's antivirus pill shows 'rapid clearance' of COVID-19